A novel mouse model for immunogenic evaluation of human HBV vaccines

Vaccine

Volumn 27, Issue 41, 2009, Pages 5692-5699

  Guo, Yingjun ^a   Ren, Ding ^a   He, Xiaowen ^a   Wang, Fang ^a   Jiang, Lei ^a   Song, Shuxia ^a   He, Ying ^a   Sun, Shuhan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CTLs; Epitope peptide vaccines; HBV HLA A2.1 dTg

Indexed keywords

EPITOPE; HEPATITIS B VACCINE; PEPTIDE VACCINE; TETRAMER; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE EXPRESSION; GENOMICS; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HEPATITIS B VACCINES; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; ORTHOHEPADNAVIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 69249220066     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.088     Document Type: Article

References (35)

1. Arbuthnot P., and Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 82 (2001) 77-100
2. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
3. Ganem D., Prince A.M., and Hepatitis. B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
4. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13 (1995) 29-60
5. Guidotti L.G. Pathogenesis of viral hepatitis. J Biol Regul Homeost Agents 17 (2003) 115-119
6. Faldella G., Galletti S., Corvaglia L., Ancora G., and Alessandroni R. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants. Vaccine 25 (2007) 1036-1042
7. Gatchalian S., Reyes M., Bernal N., Lefevre I., David M.P., Han H.H., et al. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vac 1 (2005) 198-203
8. Michel M., Lone Y.C., Centlivre M., Roux P., and Sala M. Optimisation of secretion of recombinant HBsAg virus-like particles: impact on the development of HIV-1/HBV bivalent vaccines. Vaccine 25 (2007) 1901-1911
9. Dandri M., Volz T.K., Lütgehetmann M., and Petersen J. Animal models for the study of HBV replication and its variants. J Clin Virol 34 Suppl. 1 (2005) S54-S62
10. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230 (1985) 1157-1160
11. Dunsford H.A., Sell S., and Chisari F.V. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 50 (1990) 3400-3407
12. Guidotti L.G., Matzke B., Schaller H., and Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J Virol 69 (1995) 6158-6169
13. Kim C.M., Koike K., Saito I., Miyamura T., and Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351 (1991) 317-320
14. Li X., Yang X., Jiang Y., and Liu J. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Int Immunol 17 (2005) 1293-1302
15. Zi X.Y., Yao Y.C., Zhu H.Y., Xiong J., Wu X.J., Zhang N., et al. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. Eur J Immunol 36 (2006) 875-886
16. b β2m double knockout mice. J Exp Med 185 (1997) 2043-2051
17. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S., et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169 (2002) 575-580
18. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O., et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168 (2002) 5900-5906
19. Firat H., Garcia-Pons F., Tourdot S., Pascolo S., Scardino A., Garcia Z., et al. H-2 class I knockout, HLA-A2. 1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29 (1999) 3112-3121
20. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur J Immunol 31 (2001) 3064-3074
21. Shirai M., Okada H., Nishioka M., Akatsuka T., Wychowski C., Houghten R., et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 68 (1994) 3334-3342
22. Loirat D., Mancini-Bourgine M., Abastado J.P., and Michel M.L. HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int Immunol 15 (2003) 1125-1136
23. Guilhot S., Huang S.N., Xia Y.P., La Monica N., Lai M.M., and Chisari F.V. Expression of the hepatitis delta virus large and small antigens in transgenic mice. J Virol 68 (1994) 1052-1058
24. Bertoletti A., Chisari F.V., Penna A., Guilhot S., Galati L., Missale G., et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 67 (1993) 2376-2380
25. Loirat D., Lemonnier F.A., and Michel M.L. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA based immunization. J Immunol 165 (2000) 4748-4755
26. Nayersina R., Fowler P., Guilhot S., Missale G., Cerny A., Schlicht H.J., et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150 (1993) 4659-4671
27. Ren D., Wang F., He X., Jiang L., Li D., Ying H., et al. Construction of bioactive chimeric MHC class I tetramer by expression and purification of human-murine chimeric MHC heavy chain and beta(2)m as a fusion protein in Escherichia coli. Protein Expr Purif 50 (2006) 171-178
28. Sharpe S., Hanke T., Tinsley-Bown A., Dennis M., Dowall S., McMichael A., et al. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313 (2003) 13-21
29. Sing G.K., Ladhams A., Arnold S., Parmar H., Chen X., Cooper J., et al. A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J Viral Hepat 8 (2001) 19-29
30. Gulukota K., and DeLisi C. HLA allele selection for designing peptide vaccines. Genet Anal 13 (1996) 81-86
31. Del Val M., Schlicht H.J., Ruppert T., Reddehase M.J., and Koszinowski U.H. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66 (1991) 1145-1153
32. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95 (1995) 341-349
33. Villeneuve J.P. The natural history of chronic hepatitis B virus infection. J Clin Virol 34 Suppl. 1 (2005) S139-S142
34. Gilles P.N., Fey G., and Chisari F.V. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 66 (1992) 3955-3960
35. Guilhot S., Guidotti L.G., and Chisari F.V. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a post transcriptional mechanism. J Virol 67 (1993) 7444-7449